Matter
Genentech Inc. v Novartis Pharma AG (United States District Court for the District of Columbia 25-cv-1783 (CRC))
Arbitration between Genentech Inc. and Novartis Pharma AG concerned license and collaboration agreements, Vabysmo, and territorial rights, followed by a U.S. court order recognizing and enforcing the foreign award.
Procedural record
- 14 April 2025Arbitration
14 April 2025Arbitration
Final arbitration award dated 14 April 2025
- Decision summary
- The award declared that Vabysmo (faricimab) was not a Licensed Product under the license and collaboration agreements, concluded that Vabysmo and its VEGF-binding arm were not covered by those agreements, denied Novartis's claim that Genentech breached or would continue to breach the agreements by activities concerning Vabysmo outside the United States, and ordered Novartis to pay Genentech specified arbitration costs and legal expenses with interest.
Participants
Genentech Inc.
Novartis Pharma AG
1 year, 5 months and 29 days later · 547 days
- 13 October 2026United States
13 October 2026United States
Order of the United States District Court for the District of Columbia in the case 25-cv-1783 (CRC) dated 13 October 2026
United States District Court for the District of Columbia
- Decision summary
- The court recognized and enforced the final foreign arbitral award in its entirety under 9 U.S.C. § 207 and entered judgment for Genentech Inc. against Novartis Pharma AG in accordance with the award, including the award's declarations concerning Vabysmo, rejection of Novartis's contractual claims, and monetary award of arbitration costs, legal expenses, and interest.
Participants
Genentech Inc.
Novartis Pharma AG
United States District Court for the District of Columbia
- Judge
- Christopher R. Cooper